Haoxi Health Technology Ltd Announces $4 Million Registered Direct Offering
Haoxi Health Technology Ltd (NASDAQ: HAO) said it agreed to sell 10,000,000 Class A ordinary shares, or pre-funded warrants in lieu, at $0.40 per share in a registered direct offering. Gross proceeds are expected at about $4 million, with closing around July 13, 2026, subject to conditions. Univest Securities is the placement agent.
How this was made
The 30-second read
Why it matters
A priced registered direct offering at $0.40 per share for 10,000,000 shares (or pre-funded warrants) implies immediate dilution risk, while the $4 million gross proceeds may support near-term operating needs.
Market read
Traders can model dilution and near-term financing overhang using the disclosed share count, price, and expected close date.
What to watch
The use of pre-funded warrants (exercise price $0.33) can affect effective dilution timing and investor demand dynamics into the closing window.
Background
Haoxi is a Beijing-headquartered online marketing solution provider focused on healthcare advertisers, and it filed a shelf registration statement (Form F-3) that became effective June 13, 2025.
Ticker impact
Haoxi Health Technology announced a definitive registered direct offering of 10,000,000 Class A ordinary shares at $0.40 per share, raising about $4 million.
Near-term downside bias around announcement and closing, with volatility tied to dilution expectations and any follow-on financing needs.
The article discloses deal size, pricing, share count, and expected close date (around July 13, 2026), which are direct inputs to dilution and liquidity expectations.
Market effects
Adds to the pattern of small-cap healthcare marketing firms using registered direct offerings to fund operations.
Limited direct impact beyond sentiment for China-focused ADR/Nasdaq microcaps.
Low, as proceeds are small and the transaction is company-specific.
Counterpoint
If the company uses the proceeds to accelerate customer acquisition or improve margins, the cash infusion could offset dilution concerns over subsequent quarters.
Key entities
- issuerHaoxi Health Technology Ltd
Nasdaq-listed company announcing the registered direct offering and expected closing around July 13, 2026.
- placement_agentUnivest Securities, LLC
Sole placement agent for the registered direct offering.
- regulatory_filingSEC Form F-3 (File No. 333-287686)
Shelf registration statement referenced as the basis for the offering.
